These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 2022745)

  • 41. Comparison of a new chemiluminescent immunoassay for von Willebrand factor activity with the ristocetin cofactor-induced platelet agglutination method.
    Cabrera N; Moret A; Caunedo P; Cid AR; Vila V; España F; Aznar JA
    Haemophilia; 2013 Nov; 19(6):920-5. PubMed ID: 23730809
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Four agglutination assays evaluated for measurement of von Willebrand factor (ristocetin cofactor activity).
    Ermens AA; de Wild PJ; Vader HL; van der Graaf F
    Clin Chem; 1995 Apr; 41(4):510-4. PubMed ID: 7720238
    [TBL] [Abstract][Full Text] [Related]  

  • 43. ADP-induced inhibition of von Willebrand factor-mediated platelet agglutination.
    Grant RA; Zucker MB; McPherson J
    Am J Physiol; 1976 May; 230(5):1406-10. PubMed ID: 818909
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A paradoxical effect of antibody concentration on vWF-dependent platelet agglutination distinguishes between botrocetin and ristocetin-induced agglutination.
    Roberson DW; Upchurch GR; Lamb MA; Read MS; Wagner RH; Cooper HA
    Thromb Res; 1986 Dec; 44(6):749-60. PubMed ID: 3492062
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Von Willebrand factor with increased binding capacity is associated with reduced platelet aggregation but enhanced agglutination in COVID-19 patients: another COVID-19 paradox?
    Ruberto F; Chistolini A; Curreli M; Frati G; Marullo AGM; Biondi-Zoccai G; Mancone M; Sciarretta S; Miraldi F; Alessandri F; Ceccarelli G; Barone F; Santoro C; Alvaro D; Pugliese F; Pulcinelli FM;
    J Thromb Thrombolysis; 2021 Jul; 52(1):105-110. PubMed ID: 33387210
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Structural aspects of heparin responsible for interactions with von Willebrand factor.
    Poletti LF; Bird KE; Marques D; Harris RB; Suda Y; Sobel M
    Arterioscler Thromb Vasc Biol; 1997 May; 17(5):925-31. PubMed ID: 9157957
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Measurement of platelet von Willebrand factor is dependent on method of platelet isolation.
    Solymoss S; Golden EA; Bovill EG
    Am J Clin Pathol; 1990 Mar; 93(3):400-3. PubMed ID: 2309661
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Heparin-associated thrombocytopenia: observations on the mechanism of platelet aggregation.
    Adelman B; Sobel M; Fujimura Y; Ruggeri ZM; Zimmerman TS
    J Lab Clin Med; 1989 Feb; 113(2):204-10. PubMed ID: 2783722
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Binding of porcine von Willebrand factor to human platelets in the presence of ristocetin.
    Silber P; Finlay TH
    Thromb Res; 1982 Jun; 26(5):351-8. PubMed ID: 7164028
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mechanism of inhibition by trinitrophenylation of the ristocetin cofactor activity of von Willebrand factor.
    Santoro SA; Cowan JF
    Biochim Biophys Acta; 1984 Feb; 797(2):178-85. PubMed ID: 6607747
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Spray-dried plasma deficient in high-molecular-weight multimers of von Willebrand factor retains hemostatic properties.
    Meledeo MA; Liu QP; Peltier GC; Carney RC; McIntosh CS; Taylor AS; Bynum JA; Pusateri AE; Cap AP
    Transfusion; 2019 Feb; 59(2):714-722. PubMed ID: 30450617
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Fluorescent indicators give biased estimates of intracellular free calcium change in aggregating platelets: implication for studies with human von Willebrand factor.
    Kermode JC; Zheng Q; Cook EP
    Blood Cells Mol Dis; 1996; 22(3):238-53. PubMed ID: 9075574
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Parallel determination of von Willebrand factor--Ristocetin and Botrocetin cofactors.
    Thomas KB; Tune EP; Choong SC
    Thromb Res; 1994 Aug; 75(4):401-8. PubMed ID: 7997978
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The bleeding time in normal subjects is mainly determined by platelet von Willebrand factor and is independent from blood group.
    Rodeghiero F; Castaman G; Ruggeri M; Tosetto A
    Thromb Res; 1992 Mar; 65(4-5):605-15. PubMed ID: 1615498
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of vancomycin on ristocetin and bovine PAF-induced agglutination of human platelets.
    Baugh RF; Jacoby C; Brown JE; Hougie C
    Thromb Res; 1978 Mar; 12(3):511-21. PubMed ID: 306689
    [No Abstract]   [Full Text] [Related]  

  • 56. Automated assays for von Willebrand factor activity.
    Higgins RA; Goodwin AJ
    Am J Hematol; 2019 Apr; 94(4):496-503. PubMed ID: 30592326
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Platelet von Willebrand factor assay: results using two methods for platelet lysis.
    Rodeghiero F; Castaman GC; Tosetto A; Lattuada A; Mannucci PM
    Thromb Res; 1990 Jul; 59(2):259-67. PubMed ID: 2237811
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of heparin and heparin fractions on platelet aggregation.
    Salzman EW; Rosenberg RD; Smith MH; Lindon JN; Favreau L
    J Clin Invest; 1980 Jan; 65(1):64-73. PubMed ID: 6243142
    [TBL] [Abstract][Full Text] [Related]  

  • 59. von Willebrand factor binds specifically to sulfated glycolipids.
    Roberts DD; Williams SB; Gralnick HR; Ginsburg V
    J Biol Chem; 1986 Mar; 261(7):3306-9. PubMed ID: 3485094
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The effect of heparin on the interaction of factor VIII and human platelets in vitro.
    de Marco L; Fabris F; Molaro G; Girolami A
    Haemostasis; 1977; 6(3):163-70. PubMed ID: 885379
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.